Expression of miR-210 in relation to other measures of hypoxia and prediction of benefit from hypoxia modification in patients with bladder cancer
The addition of hypoxia modifiers carbogen and nicotinamide (CON) to radiotherapy (RT) improved overall survival (OS) in bladder cancer patients in the BCON phase III clinical trial. We investigate whether expression of hsa-miR-210 in BCON patient samples reflects hypoxia and predicts benefit from h...
Main Authors: | Irlam-Jones, J, Eustace, A, Denley, H, Choudhury, A, Harris, A, Hoskin, P, West, C |
---|---|
פורמט: | Journal article |
שפה: | English |
יצא לאור: |
Cancer Research UK
2016
|
פריטים דומים
-
A gene signature for selecting benefit from hypoxia modification of radiotherapy for high risk bladder cancer patients
מאת: Yang, L, et al.
יצא לאור: (2017) -
A 26-gene hypoxia signature predicts benefit from hypoxia-modifying therapy in laryngeal cancer but not bladder cancer.
מאת: Eustace, A, et al.
יצא לאור: (2013) -
Necrosis predicts benefit from hypoxia-modifying therapy in patients with high risk bladder cancer enrolled in a phase III randomised trial
מאת: Eustace, A, et al.
יצא לאור: (2013) -
Necrosis predicts benefit from hypoxia-modifying therapy in patients with high risk bladder cancer enrolled in a phase III randomised trial.
מאת: Eustace, A, et al.
יצא לאור: (2013) -
Impact of Hypoxia-Induced miR-210 on Pancreatic Cancer
מאת: Mutian Lian, et al.
יצא לאור: (2023-12-01)